Uso de la mamografía de tamizaje en las pacientes con diagnóstico con cáncer de seno en el Hospital Universitario San Ignacio, Centro Javeriano de Oncología
Publicado
mar 6, 2010
Almetrics
Dimensions
Google Scholar
##plugins.themes.bootstrap3.article.details##
Resumen
Introducción. Actualmente el cáncer de seno ha logrado trascender en la salud de las mujeres colombianas, por ser una enfermedad con alta mortalidad. Hoy por hoy, se ofrece tamizaje de oportunidad con mamografía para mujeres mayores de 50 años, pero aún es escasa la información sobre cómo se están detectando los nuevos casos en Colombia.
Keywords
neoplasias de la mama, mamografía, tamizaje, Colombia
References
1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 2.0. IARC Cancer Base Nº 5. Lyon: IARC Press. 2001.
2. Schwarstsmann G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol. 2001;19(Suppl.18):118S-24S.
3. Piñeros M, Hernández G, Bray F. Increasing mortality rate of common malignancies in Colombia: an emerging problem. Cancer. 2004;101:2285-92.
4. Vogel, VG. Breast Cancer prevention: a review of current evidence. CA Cancer J Clin. 2000; 50:156-70.
5. Shapiro S. Periodic screening for breast cancer: The HIP randomized controlled trial. Health insurance plan. J Natl Cancer Ins Monogr.
1997;22:27-30.
6. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo mammographic
screening program. J Natl Cancer Inst Monogr. 1997;22:63-7.
7. Tabar L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, et al. the Swedish two/country trial twenty years later. Updated mortality results and new insights from long/term follow up. Radiol Clin North Am. 2000; 38:625-51.
8. Alexander FE, Anderson TJ, Brown HK, Forrest Ap, Hepburn W, Kirkpatrick AE, et al. 14 years follow up from the Edinburgh randomized trial of breast cancer screening. Lancet. 1999;353: 1903-8.
9. Miller AB, To T, Baines CJ, Wall C. Canadian Breast Screening study-2: 13 year results of a randomized trial in women aged 50-59 years. J
Natl Cancer Inst. 2000;92:1490-9.
10. Miller AB, To T, Baines CJ, Wall C. The Canadian Breast Screening study1; Breast cancer mortality after 11 to 16 years of follow up: a randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002; 137:305-15.
11. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, et al. The Golthenburg Breast Screening Trial. Cancer. 2003; 97:2387-96.
12. Ballard-Barbash R, Klabunde C, Paci E, Broeders M, Coleman EA, Fracheboud J, Bouchard F, Rennert G, Linos A, Shapiro S. International Breast Cancer Screening Network (IBSN). Breast cancer screening in 21 countries: delivery of services, notification of results, and outcomes ascertainment. Eur J Cancer Prev. 1999; 8:417-26.
13. Anderson Bo, Braun S, Lim S, Smith RA, Taplin S, Thomas DB, et al. Early detection of breast cancer in countrieswith limited resources. Breast J. 2003;9(Suppl.2):S51-9.
14. República de Colombia. Ministerio de la Protección Social, Instituto Nacional de Cancerología. Recomendaciones para la detección temprana del cáncer de mama en Colombia. Bogotá: Instituto Nacional de Cancerología. 2007.
15. Suter LG, Nakano CJ, Elmore JG. The personal costs and convenience of screening mammography. J Womens Health Gend Based Med. 2002;11: 667-72.
16. Pearlman DN, Rakowski W, Ehrich B. Mammography, clinical breast exam, and Pap testing: correlates of combined screening. Am
J Prev Med. 1996;12:57-64,.
17. República de Colombia. Ministerio de Salud. Resolución 412, 25 de febrero de 2000, por la cual se establecen las actividades, procedimientos e intervenciones de demanda inducida y obligatorio
cumplimiento y se adoptan las normas técnicas y guías de atención
para el desarrollo de las acciones de protección específica, detección
temprana y la atención de enfermedades de interés en salud pública. Bogotá: Imprenta Nacional. 2000.
18. Lannin DR, Mathews HF, Miychell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA. 1998;279:1801-7.
19. Whitman G, Sheppard D, Phelps M. Breast cancer staging. Semin Roentgenol. 2006;41:91-104.
20. Barth RJ, Gibson GR, Carney PA, Mott LA, Becher RD, Poplack SP. Detection of breast cancer on screening mammography allows patients to be treated with less-toxic therapy. AJR. 2005;184:324-9.
21. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365:1727-41.
22. Jonsson H, Nyström L, Törnberg S, Lundgren B, Lenner P. Service screening with mammography. Long term effects on breast cancer mortality in the county of Gävleborg, Sweden. Breast. 2003;12:183-93.
23. Seltzer MH. Breast complaints, biopsies, and cancer correlated with age in 10,000 consecutive new surgical referrals. Breast J. 2004;10:111-7.
24. Spencer DB, Potter JE, Chung MA, Fulton J, Hebert W, Cady B. Mammographic screening and disease presentation of breast cancer patients who die of disease. Breast J. 2004;10:298-303.
25. Gill PG, Farshid G, Luke CG, Roder DM. Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast. 2004;13:15-22.
26. Buitatti E, Barchielli A, Bartolacci S, Federico M, De Lisi V, Bucchi L, et al. The impact of organized screening programmes on the stage-specific incidence of breast cancer in some Italian areas. Eur
J Cancer. 2003;39:1776-82.
27. Robledo JF, Caicedo JJ, Deantonio R. Análisis de sobrevida en una cohorte de 1328 pacientes con carcinoma de seno. Rev Colomb Cir. 2005; 20:4-20.
28. Piñeros M, Sánchez R, Cendales R, Perry F, Ocampo R, García OA.
Características sociodemográficas, clínica y de la atención de mujeres con cáncer de mama en Bogotá. Rev Colomb Cancerol. 2008; 12:181-90.
29. Canadian Society for Surgical Oncology position statement. Fecha de
consulta: 13 de marzo de 2009. Disponible en: http://www.cos.ca/csso.
30. Robinson D, Bell CM, Møller H, Basnet I, Effect of the UK government’s 2week target on waiting times in women with
breast cancer in southeast England. Br J Cancer. 2003;89:492-6.
31. Ramírez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet. 1999;353: 1127-31.
32. Burgess CC, Ramírez AJ, Richards MA, Love SB. Who and what influences delayed presentation in breast cancer? Br J Cancer. 1998;77:1343-8.
33. González-Mariño MA. Cáncer de seno en la Clínica San Pedro Claver de Bogotá, 2004. Rev Salud Pública. 2006;8:163-9.
34. Pardo C, Murillo R. Casos nuevos de cáncer en el Instituto Nacional de Cancerología, Colombia. Rev Col de Cancerol. 2002;7:4-19.
35. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000;355:1822.
36. Hermon C, Beral V. Breast cancer mortality rates are leveling off or beginning to decline in many western countries: analysis of time trends, agecohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer. 1996;73:955-60.
2. Schwarstsmann G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol. 2001;19(Suppl.18):118S-24S.
3. Piñeros M, Hernández G, Bray F. Increasing mortality rate of common malignancies in Colombia: an emerging problem. Cancer. 2004;101:2285-92.
4. Vogel, VG. Breast Cancer prevention: a review of current evidence. CA Cancer J Clin. 2000; 50:156-70.
5. Shapiro S. Periodic screening for breast cancer: The HIP randomized controlled trial. Health insurance plan. J Natl Cancer Ins Monogr.
1997;22:27-30.
6. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo mammographic
screening program. J Natl Cancer Inst Monogr. 1997;22:63-7.
7. Tabar L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, et al. the Swedish two/country trial twenty years later. Updated mortality results and new insights from long/term follow up. Radiol Clin North Am. 2000; 38:625-51.
8. Alexander FE, Anderson TJ, Brown HK, Forrest Ap, Hepburn W, Kirkpatrick AE, et al. 14 years follow up from the Edinburgh randomized trial of breast cancer screening. Lancet. 1999;353: 1903-8.
9. Miller AB, To T, Baines CJ, Wall C. Canadian Breast Screening study-2: 13 year results of a randomized trial in women aged 50-59 years. J
Natl Cancer Inst. 2000;92:1490-9.
10. Miller AB, To T, Baines CJ, Wall C. The Canadian Breast Screening study1; Breast cancer mortality after 11 to 16 years of follow up: a randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002; 137:305-15.
11. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, et al. The Golthenburg Breast Screening Trial. Cancer. 2003; 97:2387-96.
12. Ballard-Barbash R, Klabunde C, Paci E, Broeders M, Coleman EA, Fracheboud J, Bouchard F, Rennert G, Linos A, Shapiro S. International Breast Cancer Screening Network (IBSN). Breast cancer screening in 21 countries: delivery of services, notification of results, and outcomes ascertainment. Eur J Cancer Prev. 1999; 8:417-26.
13. Anderson Bo, Braun S, Lim S, Smith RA, Taplin S, Thomas DB, et al. Early detection of breast cancer in countrieswith limited resources. Breast J. 2003;9(Suppl.2):S51-9.
14. República de Colombia. Ministerio de la Protección Social, Instituto Nacional de Cancerología. Recomendaciones para la detección temprana del cáncer de mama en Colombia. Bogotá: Instituto Nacional de Cancerología. 2007.
15. Suter LG, Nakano CJ, Elmore JG. The personal costs and convenience of screening mammography. J Womens Health Gend Based Med. 2002;11: 667-72.
16. Pearlman DN, Rakowski W, Ehrich B. Mammography, clinical breast exam, and Pap testing: correlates of combined screening. Am
J Prev Med. 1996;12:57-64,.
17. República de Colombia. Ministerio de Salud. Resolución 412, 25 de febrero de 2000, por la cual se establecen las actividades, procedimientos e intervenciones de demanda inducida y obligatorio
cumplimiento y se adoptan las normas técnicas y guías de atención
para el desarrollo de las acciones de protección específica, detección
temprana y la atención de enfermedades de interés en salud pública. Bogotá: Imprenta Nacional. 2000.
18. Lannin DR, Mathews HF, Miychell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA. 1998;279:1801-7.
19. Whitman G, Sheppard D, Phelps M. Breast cancer staging. Semin Roentgenol. 2006;41:91-104.
20. Barth RJ, Gibson GR, Carney PA, Mott LA, Becher RD, Poplack SP. Detection of breast cancer on screening mammography allows patients to be treated with less-toxic therapy. AJR. 2005;184:324-9.
21. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365:1727-41.
22. Jonsson H, Nyström L, Törnberg S, Lundgren B, Lenner P. Service screening with mammography. Long term effects on breast cancer mortality in the county of Gävleborg, Sweden. Breast. 2003;12:183-93.
23. Seltzer MH. Breast complaints, biopsies, and cancer correlated with age in 10,000 consecutive new surgical referrals. Breast J. 2004;10:111-7.
24. Spencer DB, Potter JE, Chung MA, Fulton J, Hebert W, Cady B. Mammographic screening and disease presentation of breast cancer patients who die of disease. Breast J. 2004;10:298-303.
25. Gill PG, Farshid G, Luke CG, Roder DM. Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast. 2004;13:15-22.
26. Buitatti E, Barchielli A, Bartolacci S, Federico M, De Lisi V, Bucchi L, et al. The impact of organized screening programmes on the stage-specific incidence of breast cancer in some Italian areas. Eur
J Cancer. 2003;39:1776-82.
27. Robledo JF, Caicedo JJ, Deantonio R. Análisis de sobrevida en una cohorte de 1328 pacientes con carcinoma de seno. Rev Colomb Cir. 2005; 20:4-20.
28. Piñeros M, Sánchez R, Cendales R, Perry F, Ocampo R, García OA.
Características sociodemográficas, clínica y de la atención de mujeres con cáncer de mama en Bogotá. Rev Colomb Cancerol. 2008; 12:181-90.
29. Canadian Society for Surgical Oncology position statement. Fecha de
consulta: 13 de marzo de 2009. Disponible en: http://www.cos.ca/csso.
30. Robinson D, Bell CM, Møller H, Basnet I, Effect of the UK government’s 2week target on waiting times in women with
breast cancer in southeast England. Br J Cancer. 2003;89:492-6.
31. Ramírez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet. 1999;353: 1127-31.
32. Burgess CC, Ramírez AJ, Richards MA, Love SB. Who and what influences delayed presentation in breast cancer? Br J Cancer. 1998;77:1343-8.
33. González-Mariño MA. Cáncer de seno en la Clínica San Pedro Claver de Bogotá, 2004. Rev Salud Pública. 2006;8:163-9.
34. Pardo C, Murillo R. Casos nuevos de cáncer en el Instituto Nacional de Cancerología, Colombia. Rev Col de Cancerol. 2002;7:4-19.
35. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000;355:1822.
36. Hermon C, Beral V. Breast cancer mortality rates are leveling off or beginning to decline in many western countries: analysis of time trends, agecohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer. 1996;73:955-60.
Cómo citar
Angarita, F. A., Acuña, S. A., Tawil, M., Ruiz, Álvaro J., & Torregosa, L. (2010). Uso de la mamografía de tamizaje en las pacientes con diagnóstico con cáncer de seno en el Hospital Universitario San Ignacio, Centro Javeriano de Oncología. Universitas Medica, 51(2), 155–166. https://doi.org/10.11144/Javeriana.umed51-2.umtp
Número
Sección
Artículos originales